Background
Comprehensive RNA sequencing enables unbiased detection of clinically relevant gene fusions that may be missed by DNA- or targeted RNA-based assays. We evaluated whole-transcriptome sequencing (WTS) for detection of known and novel fusions and assessed clinical outcomes associated with novel fusion partners.
Methods
WTS was performed on 698,406 solid tumors submitted for comprehensive molecular profiling (2019–2026). Fusion detection used STAR aligner,1 with pathogenic/likely pathogenic (P/LP) variants classified per American College of Medical Genetics and Genomics criteria.2 Fusions not previously reported in ClinVar3/CIViC4 reference datasets were categorized as novel fusions. Diagnostic and actionable fusions were included with level 1-3 (L1-L3) evidence associations (level 1= FDA-approved, level 2 = NCCN guided therapy, level 3 = lower tier evidence based on peer-reviewed publications or in vitro pre-clinical models).5 Overall survival (OS) was evaluated in patients with linked claims data receiving tyrosine kinase inhibitors (TKIs) or non-targeted therapies.
Results
- WTS detected fusion transcripts in 503,460 (72.1%) of 698,406 tumors.
- Among fusion-positive tumors, 37,325 (7.4%) harbored P/LP fusions.
- Among fusion-positive tumors, 34,671 (6.9%) harbored fusions with L1–L3 therapeutic or diagnostic significance.
- Among actionable fusions identified throughout the study period, >91% were novel fusion pairs
- ERG and RSPO3 were the most frequent diagnostic fusion partners.
- ALK, FGFR2, and FGFR3 were the most common actionable fusion genes.

